The investigations center on three distinct corporate moves: the $85.00 per share cash acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals, the merger between Twin Vee PowerCats and USFM Corporation, and Element Solutions’ sale to Solstice Advanced Materials. Under the terms of the Element Solutions deal, shareholders are slated to receive $10.00 in cash plus 0.500 shares of Solstice common stock, leaving them with roughly 44% of the combined entity.

Halper Sadeh attorneys are examining whether these agreements include restrictive provisions that effectively discourage superior competing bids. The firm claims that current terms may exclude ordinary shareholders from financial advantages reserved for insiders. Legal representatives are now offering consultations to affected investors to discuss potential paths for seeking increased consideration or improved disclosures through the courts.